Biosplice's Osteoarthritis Drug Among New Filings at European Medicines Agency

The European Medicines Agency (EMA) has received new drug applications for a diverse range of indications, including a disease-modifying osteoarthritis drug from Biosplice, as well as products from Novartis, MSD, and Ultragenyx for cancer, rare diseases, and neurodegenerative disorders. These filings mark the entry of these potential new therapies into the regulatory review cycle in the EU.